Shares of Ventyx Biosciences fell after the company released results from a trial of VTX002 in the treatment of moderate to severely active ulcerative colitis.
The stock was down 21% to $23.75 after-hours on Monday, after falling 0.9% at the close. Shares are down 8.5% this year.
The San Diego-based biopharmaceutical company said its Phase 2 trial found that 28% of patients receiving 60-milligram doses achieved clinical remission by week 13, compared with 11% of patients receiving placebo. About 24% of patients on the 30- milligram dose achieved remission.